Request Demo

Last update 15 Jan 2026

Vebreltinib

Last update 15 Jan 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bozitinib, 维瑞替尼, APL-101

+ [4]

Target

c-Met

Action

inhibitors

Mechanism

c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesNervous System Diseases+ [6]

Active Indication

MET gene amplification Non-small Cell Lung CancerAstrocytoma, IDH-MutantGlioblastoma+ [23]

Inactive Indication

GangliogliomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic hepatocellular carcinoma+ [1]

Originator Organization

Zhejiang Crownmab Biotech Co. Ltd.

Active Organization

Beijing Purunao Biotechnology Co Ltd

Apollomics, Inc. (United States)

Avistone Biotechnology Co., Ltd.

Inactive Organization

Apollomics (Australia) Pty Ltd.

License Organization

Sino US Guanke Biotechnology (Taicang) Co., Ltd.

Zhejiang Crownmab Biotech Co. Ltd.

LAUNXP Biomedical Co Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

China (14 Nov 2023),

MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer

RegulationOrphan Drug (United States), Breakthrough Therapy (China), Special Review Project (China), Conditional marketing approval (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC20H15F3N8

InChIKeyQHXLXUIZUCJRKV-UHFFFAOYSA-N

CAS Registry1440964-89-5

Clinical Trials associated with Vebreltinib

NCT07156604

/ Not yet recruitingPhase 2IIT

Vebreltinib for Neoadjuvant Treatment in Patients With Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) Harboring METex 14 Skipping Mutant

This is a prospective, single-center phase II clinical study aimed at evaluating the efficacy and safety of Vebreltinib in neoadjuvant treatment for patients with resectable stage IIA-IIIB (N2) non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. In the study, all eligible subjects who signed the informed consent and met the inclusion and exclusion criteria were treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery. The subjects were evaluated by the investigators and the surgical resection was performed within approximately 2 weeks after the neoadjuvant treatment. The study used RECIST v1.1 for imaging assessment. A CT or enhanced CT scan was conducted within 2 weeks after the end of treatment, and then every 180 days (±14) after surgery until 3 years, and then annually until disease recurrence or death, or the end of the study.

Start Date30 Sep 2025

Sponsor / Collaborator

Fudan University

NCT07153887

/ RecruitingPhase 2IIT

An Exploratory Clinical Trial of Vebreltinib for the Treatment of Patients With Locally Advanced or Metastatic Clear Cell Sarcoma

This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression.
Cohort 2 is external reference group. Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators. These subjects will receive follow-up. The efficacy and safety data will be collected.
Imaging evaluation will be performed using RECIST v1.1, with CT or MR plain scans every two months (±7 days) until disease recurrence or death.
During the study, subjects will receive safety follow-up, and survival follow-up will be conducted every two months after treatment, which can be done by telephone interview for approximately 3 years after treatment ends.

Start Date30 Sep 2025

Sponsor / Collaborator

The Second Affiliated Hospital Zhejiang University

NCT07153770

/ Not yet recruitingPhase 2IIT

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer

Start Date20 Sep 2025

Sponsor / Collaborator

Shanghai Pulmonary Hospital

100 Clinical Results associated with Vebreltinib

100 Translational Medicine associated with Vebreltinib

100 Patents (Medical) associated with Vebreltinib

Literatures (Medical) associated with Vebreltinib

01 Nov 2025·Bioactive Materials

A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation

Article

Author: Sun, Fei ; Liu, Tong ; Wang, Jianfeng ; Yu, Shuqing ; Yang, Bao ; Zhang, Delong ; Bao, Zhaoshi ; Feng, Yutong ; Zhao, Qian ; Fu, Yiwen ; Xing, Cencan ; Jiang, Tao ; Fang, Zheng ; Zou, Donghua ; Chen, Qiaodong ; Xiao, Bo ; Ning, Shipeng ; Zheng, Lemin ; Chen, Jiahong ; Chen, Jie ; Min, Li ; Zheng, Chengjun ; Zhang, Ying ; Wang, Peng ; Yang, Yang ; Yan, Jun

Glioma is an aggressive brain tumor with a poor prognosis. Establishing an in vitro culture model that closely replicates the cellular composition and microenvironment of the original tumor has been challenging, limiting its clinical applications. Here, we present a novel approach to generate glioma organoids with a microenvironment (GlioME) from patient-derived glioma tissue. These organoids maintain the genetic and epigenetic characteristics of the primary tumor and preserve cell-to-cell interactions within the tumor microenvironment, including resident immune cells. Bulk RNA sequencing, whole exome sequencing, and DNA methylation analysis were used to confirm the molecular similarities between the organoids and primary glioma tissues. Immunofluorescence and flow cytometry were used to assess immune cell viability, comparing GlioME with floating glioma organoids. GlioME exhibited high responsiveness to chemotherapy and targeted therapy, demonstrating its potential for therapeutic screening applications. Notably, GlioME accurately predicted patient response to the recently approved MET inhibitor, vebreltinib. Thus, this organoid model provides a reliable in vitro platform for glioma microenvironment-related research and clinical drug screening.

01 Oct 2025·Chinese Journal of Chromatography

Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry

Article

Author: Chen, Mao-Qin ; Wang, Hai-Bo ; Fan, Lei-Lei ; Yang, Qiu-Hong

According to the Safety and Technical Specification for Cosmetics （2015）， the addition of chemical drugs to cosmetics is strictly prohibited. Anti-alopecia cosmetics are often found to contain illegal additions of prohibited drugs such as minoxidil， finasteride and other substances. Ultra-high performance liquid chromatography-tandem triple quadrupole-linear ion trap mass spectrometry （UHPLC-Q-TRAP/MS） has become a powerful technology for the simultaneous detection of illegal ingredients in cosmetics due to its advantages of rapid analysis， high sensitivity， high throughput and high selectivity. An ultra-high performance liquid chromatography-multiple reaction monitoring-information dependent acquisition-enhanced production scanning （UHPLC-MRM-IDA-EPI） method was developed to determine 13 JAK inhibitors in anti-alopecia cosmetics， including baricitinib， tofacitinib， ritlecitinib， peficitinib， abrocitinib， upadacitinib， ivarmacitinib， fedratinib， filgotinib， ruxolitinib， momelotinib， pacritinib and bozitinib. The influence of extraction solvents was investigated. Approximately 0.2 g of the sample was weighed and placed in a 50 mL graduated centrifuge tube with a cap. Then， 2 mL of 0.1% （v/v） aqueous formic acid and 10 mL of acetonitrile were added， followed by vortexing for 1 min. Subsequently， the mixture was sonicated in an ultrasonic bath for 15 min. Added 0.5 g of sodium chloride， and the mixture was centrifuged at 8 000 r/min for 8 min at 5 °C. The supernatant was transferred to another 50 mL graduated centrifuge tube with a cap. The residue was added with 10 mL of acetonitrile and the extraction procedure was repeated. After high-speed centrifugation， the supernatant was combined. The combined supernatant was added with 0.2 g of sodium chloride， and the mixture was frozen at ‒20 °C for 1 h. It was centrifuged at 8 000 r/min for 5 min at 5 °C. The acetonitrile layer was collected and filtered through a 0.22 μm organic filter membrane. The initial filtrate was discarded， and the subsequent filtrate was collected as the sample solution. A C₁₈ column was used for chromatographic separation， enabling the successful separation of the analytes within 10 min. The mobile phase consisted of 0.1% （v/v） aqueous formic acid and acetonitrile， with gradient elution applied to optimize separation efficiency. The flow rate was set at 0.3 mL/min， and the column temperature was maintained at 40 ℃ to ensure consistent performance. A fixed injection volume of 2 μL was used to guarantee reproducibility and accuracy in the analysis. This configuration enabled the rapid and reliable separation of the target compounds. For the analysis of the 13 kinds of JAK inhibitors， an ESI source operating in positive ion mode was used with MRM-IDA-EPI detection. Quantification was performed by the external standard method using matrix-matched standard solutions. Good separation of the 13 JAK inhibitors was achieved under the optimized chromatographic conditions. Calibration curves were constructed by plotting the peak area of quantitative ions against the compound mass concentration. These curves exhibited excellent linearity within the investigated concentration range， with r all exceeding 0.996. The limits of detection （LODs） and limits of quantification （LOQs） of the 13 JAK inhibitors were 1.5-1.7 ng/g and 9.2-10.9 ng/g. To validate accuracy and precision， two cosmetic matrices （water-soluble and cream） were tested at three levels： LOQ， 2×LOQ and 10×LOQ. Recoveries of the 13 JAK inhibitors ranged from 94.7% to 102.2% for the water-soluble matrix and from 92.4% to 99.2% for the cream matrix， with relative standard deviations （RSDs） ≤8.8%. This method is characterized by high efficiency， rapidity， accuracy， sensitivity and simplicity， making it a powerful tool for rapid risk screening and simultaneous quantitative analysis of JAK inhibitors in anti-alopecia cosmetics.

01 Jun 2025·Thoracic Cancer

Enhancing the Precision and Efficiency of Pulmonary Tumor Detection With Robotic‐Assisted ¹⁸F‐FDG PET/CT‐Guided Lung Biopsy: A Case Report

Article

Author: Liu, Jian ; Xu, Chuan ; Lu, Xia ; Li, Haiyan ; Niu, Bing ; Xu, Kai

ABSTRACT:

Sarcomatoid carcinoma, a rare and aggressive form of non‐small cell lung cancer, presents diagnostic challenges due to its heterogeneity and atypical features. This case report evaluates robotic‐assisted 18F‐FDG PET/CT‐guided percutaneous lung biopsy for improving diagnostic accuracy and efficiency in such complex lung lesions. We present the case of an 86‐year‐old male with a right upper lung lesion, chronic cough, intermittent hemoptysis, chills, and fever. Initial fiberoptic bronchoscopy and CT‐guided lung biopsy (16 min, three needle adjustments) were inconclusive. Subsequently, a robotic‐assisted PET/CT‐guided percutaneous lung biopsy was performed, targeting metabolically active regions. This procedure was completed in 6 min without any needle adjustments. This efficiency stemmed from the system's clear, precise navigation, eliminating extensive manual lesion localization and collision risk with critical structures. Unlike some navigated procedures, it avoids time‐consuming marker placement and registration. Its high accuracy guidance facilitated single needle insertion, preventing repeated adjustments, confirmatory CTs, and step‐by‐step needle advancement. Imaging confirmed a hypermetabolic lesion and mediastinal lymphadenopathy suggestive of malignancy, and histopathology revealed sarcomatoid carcinoma with pleomorphic atypical cell infiltration, high mitotic activity, and necrosis. Genetic testing identified a MET mutation, leading to targeted therapy with Bozitinib. Follow‐up imaging at 1 month showed a significant reduction in the lesion size, indicating a positive treatment response. This case underscores the potential advantages of robotic‐assisted 18F‐FDG PET/CT‐guided lung biopsy in enhancing diagnostic sensitivity and procedural efficiency by precisely targeting metabolically active areas, minimizing needle adjustments, and potentially reducing false‐negative results. Broader application in interventional radiology and oncology warrants further investigation.

News (Medical) associated with Vebreltinib

23 Dec 2025

·www.biospace.com

Apollomics Reports First Half 2025 Financial Results

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 2024. Based on current projections, the Company believes its cash position is sufficient to fund planned operations into the third quarter of 2026. Research and development (R&D) expenses were $4.6 million, including share-based compensation of $0.8 million, for the first half of 2025, compared to $16.9 million, including share-based compensation of $3.7 million, for the first half of 2024. General and administrative (G&A) expenses were $14.5 million, including share-based compensation of $2.5 million, for the first half of 2025, compared to $10.2 million, including share-based compensation of $4.5 million, for the first half of 2024. Net loss for the first half of 2025 was $(12.5) million, or $(11.37) per basic and diluted share, compared to a net loss of $(35.2) million, or $(37.53) per basic and diluted share, for the first half of 2024. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit . Cautionary Statement Regarding Forward-Looking Statements This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents or to be by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contacts Peter Lin, Chief Financial Officer Apollomics, Inc. 1-650-209-4055 peter.lin@apollomicsinc.com Peter Vozzo ICR Healthcare 1-443-213-0505 Peter.Vozzo@icrhealthcare.com APOLLOMICS INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (All amounts in thousands of $) As of June 30, 2025 (Unaudited) As of December 31, 2024 Non-current assets Plant and equipment, net $ 10 $ 92 Right-of-use assets 670 927 Intangible assets, net 228 1,737 Rental deposits 82 75 Total non-current assets 990 2,831 Current assets Deposits, prepayments and deferred expenses 835 501 Accounts receivable 7,200 — Cash and cash equivalents 2,094 9,766 Total current assets 10,129 10,267 Total assets 11,119 13,098 Current liabilities Other payables and accruals 10,269 7,166 Lease liabilities, current portion 203 233 Total current liabilities 10,472 7,399 Net current (liabilities) assets (343 ) 2,868 Total assets less current liabilities 647 5,699 Non-current liabilities Lease liabilities, non-current portion 541 733 Warrant liabilities at fair value through profit and loss (“FVTPL”) 486 102 Other non-current liabilities 4,018 — Total non-current liabilities 5,045 835 Net (liabilities) assets (4,398 ) 4,864 Equity Share capital 11 11 Share premium 666,528 666,528 Reserves 42,422 39,148 Accumulated deficits (713,359 ) (700,823 ) Total (deficit) equity $ (4,398 ) $ 4,864 APOLLOMICS INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (UNAUDITED) (All amounts in thousands of $, except for per share data) Six Months Ended June 30, 2025 2024 Revenue $ 8,500 $ — Other income 83 1,737 Foreign exchange losses (77 ) (2 ) Fair value change of financial assets at FVTPL — 198 Fair value change of financial liabilities at FVTPL (384 ) 164 Research and development expenses (4,620 ) (16,926 ) Administrative expenses (14,488 ) (10,153 ) Impairment of intangible assets (1,500 ) (10,000 ) Finance costs (35 ) (134 ) Other expense (14 ) (90 ) Loss before taxation (12,535 ) (35,206 ) Income tax expenses (1 ) 0 Loss and total comprehensive loss for the period, net of taxation, attributable to owners of the Company $ (12,536 ) $ (35,206 ) Loss per share Basic loss per common share $ (11.37 ) $ (37.53 ) Diluted loss per common share $ (11.37 ) $ (37.53 ) Weighted average number of common shares outstanding – Basic and Diluted 1,103 938

Financial StatementPhase 2Phase 1

18 Nov 2025

·www.globenewswire.com

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors. Biographical Information of the New Director Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan's biopharmaceutical industry. Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics. Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond's portfolio companies. She participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities' investment banking profits. Dr. Huang's scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award. Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University. About Apollomics Inc.Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking StatementsThis press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contacts: Apollomics: Peter Lin, Chief Financial Officer Apollomics, Inc. Phone: 1-650-209-4055 Email: peter.lin@apollomicsinc.com

Phase 2Executive ChangeIPO

14 Oct 2025

·endpoints.news

FDA delays decision on Denali drug; Astellas’ Vyloy fails mid-stage pancreatic cancer trial

Plus, news about Spyre Therapeutics, Candel Therapeutics, Boehringer Ingelheim, Quantro Therapeutics, Clover, EVerZom and Apollomics: 🏛️ FDA pushes back decision on Denali Therapeutics’ Hunter syndrome treatment: The company is seeking accelerated approval of tividenofusp alfa for mucopolysaccharidosis type II. The PDUFA date is now April 5, three months later than expected. Denali’s stock price $DNLI was down about 4% on Tuesday morning, the day after it announced the delay. — Jaimy Lee 📉 Astellas’ Vyloy fails Phase 2 trial in pancreatic cancer: The Japanese drugmaker had been testing the drug in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. The study did not meet the primary endpoint of overall survival. There will be “minor” impact to Astellas’ financial results, the company said. — Jaimy Lee 💰 Spyre Therapeutics’ $275M offering: The company is selling about 14.9 million shares at $18.50 apiece. — Jaimy Lee 💸 Candel Therapeutics inks $130M loan agreement: The five-year loan facility, which is being funded by Trinity Capital, consists of five tranches, including an initial $50 million tranche when the deal closes. The cash should support Candel as it eyes starting a Phase 3 trial of CAN-2409 in non-small cell lung cancer in the second quarter of 2026. Its share price $CADL dropped about 7% on Tuesday morning. — Ayisha Sharma 🫱🏼‍🫲🏽 Boehringer Ingelheim extends work with Quantro Therapeutics: The companies, which announced the up to €500 million (about $580 million) deal in 2022, have now extended the collaboration for two more years. They’re working on therapies that target cancer-associated transcription factors. Financial terms of the extension were not disclosed. — Jaimy Lee 🍀 Clover’s Phase 1 RSV data: The Shanghai-based biotech’s vaccine candidates, SCB-1022 and SCB-1033, produced an average six- to eight-fold increase in neutralizing antibodies against RSV in a trial of older adults in Australia. Both assets are combination vaccines designed to protect against multiple respiratory diseases. — Ayisha Sharma 💶 EVerZom raises €10M: The French biotech is developing exosome-based biotherapies for inflammatory diseases. It now plans to move its candidate into the clinic for Crohn’s perianal fistula next year. — Jaimy Lee 💼 Apollomics is no longer winding down: The biotech, which in August announced plans to discontinue work on its small molecule c-Met inhibitor, said it has since received funding to stay in business. Apollomics now has a new board and a new leadership team. Its main asset, APL-101, is currently in Phase 2. — Jaimy Lee

VaccinePhase 2Clinical ResultPhase 1

100 Deals associated with Vebreltinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
MET gene amplification Non-small Cell Lung Cancer	China	Beijing Purunao Biotechnology Co Ltd	24 Jun 2025
Astrocytoma, IDH-Mutant	China	Beijing Purunao Biotechnology Co Ltd	17 Apr 2024
Glioblastoma	China	Beijing Purunao Biotechnology Co Ltd	17 Apr 2024
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	China	Beijing Purunao Biotechnology Co Ltd	14 Nov 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
c-Met positive stomach adenocarcinoma	Phase 3	China	Beijing Purunao Biotechnology Co Ltd	07 Jul 2025
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	China	Beijing Purunao Biotechnology Co Ltd	07 Jul 2025
Non-Small Cell Lung Cancer	Phase 3	-	Avistone Biotechnology Co., Ltd.	15 May 2025
Prostatic Cancer	Phase 3	-	Avistone Biotechnology Co., Ltd.	15 May 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Avistone Biotechnology Co., Ltd.	07 Aug 2024
EGFR-mutated non-small Cell Lung Cancer	Phase 2	United States	Apollomics, Inc. (United States)	18 Jan 2022
metastatic non-small cell lung cancer	Phase 2	United States	Apollomics, Inc. (United States)	18 Jan 2022
Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Beijing Purunao Biotechnology Co Ltd	17 Jan 2020
c-Met positive non-small cell lung cancer	Phase 2	China	Beijing Purunao Biotechnology Co Ltd	06 Jan 2020
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	Australia	Apollomics (Australia) Pty Ltd.	05 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04258033 (KUNPENG, ESMO_ASIA2025 \| NEWS) Manual	Phase 2	MET gene amplification Non-small Cell Lung Cancer MET Amplification	86	Vebreltinib 200 mg (chemo-untreated pts)	nfmiujbkap(pzmsltxztu) = tgujomhrbi xflifwmuyi (chjuhvvefr, 38.7 - 64.9) View more	Positive	06 Dec 2025
				Vebreltinib 200 mg (chemo-treated pts)	nfmiujbkap(pzmsltxztu) = luutevivxx xflifwmuyi (chjuhvvefr, 25.6 - 61.1) View more
NCT04258033 (KUNPENG, Pubmed \| Lancet Oncol)	Phase 2	MET gene amplification Non-small Cell Lung Cancer MET amplification	86	Vebreltinib 200 mg	flpkerccyo(qnlfdpqfxm) = datbnvfuro uypluywwuj (gxevhithxb ) View more	Positive	01 Dec 2025
NCT04258033 (KUNPENG, Company_Website) Manual	Phase 2	Non-Small Cell Lung Cancer MET Amplification	86	伯瑞替尼	abjtiintua(nmeszcxosz) = nlenvvnkpr hbauqxscgd (eykfdvbrsj ) View more	Positive	30 Jun 2025
				伯瑞替尼 (队列2：标准治疗（含铂化疗方案）失败的MET扩增经治患者)	abjtiintua(nmeszcxosz) = tomsuwxvzu hbauqxscgd (eykfdvbrsj ) View more
NCT06343064 (phase Ib/II study, ASCO2025)	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer METamp positive \| METov	56	Vebreltinib 150 mg BID + PLB1004 80 mg QD	yvsbqaedwe(xskbdlilza) = 60.7% jkazuuoqpq (tmdhjpsgzt ) View more	Positive	30 May 2025
NCT04258033 \| NCT03175224 (SPARTA-II, ESMO2024) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping	107	Vebreltinib 200 mg BID	dgguajykzu(euenvchtyo) = cwnnirzdrx klvrjrvyfr (lgeumiylyp ) View more	Positive	14 Sep 2024
				Vebreltinib Vebreltinib 200 mg BID (previously treated)	ssilcopszg(ciyxpfbnce) = mbvlmnpkkg ciwhxqqtlq (spaoxqlivo, 43.5 - 76.9) View more
NCT06343064 (WCLC2024) Manual	Phase 1/2	EGFR mutation MET positive Non-small Cell Lung Cancer MET Overexpression \| MET Amplification \| EGFR Mutation	44	Vebreltinib 100mg plus PLB1004 160mg	fslbxmyzrr(tghgnvaels) = wpwrqlmekx bwctqcwklb (ebgqcktpbq )	Positive	10 Sep 2024
				Vebreltinib 150mg plus PLB1004 160mg	fslbxmyzrr(tghgnvaels) = xkpaugwcgq bwctqcwklb (ebgqcktpbq )
NCT03175224 (SPARTA, GlobeNewswire) Manual	Phase 2	Solid tumor MET Fusion	14	Vebreltinib	gbculrauvp(vgawseyjyw) = giysfetoyy iowjfstpya (dpwcnwctys ) View more	Positive	13 Aug 2024
NCT04258033 (KUNPENG, Literature \| Pubmed \| J Clin Oncol) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping (Activating)	52	Vebreltinib 200 mg	mkonjgdesx(chkfibonrl) = xvfiotmetx yqwwqpxose (hfhdaxqwwe, 61.1 - 86) View more	Positive	26 Jul 2024
				Vebreltinib 200 mg (treatment-naïve)	mkonjgdesx(chkfibonrl) = gyhgjyzdsu yqwwqpxose (hfhdaxqwwe, 59.9 - 89.6)
NCT04258033 (KUNPENG, ASCO2024) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping	135	Vebreltinib 200 mg	emyqicjmmi(yofztithgu) = nkdsjpgsxc pxkteiyzlb (zggnwnlfzj, 61.1 - 86.0) View more	Positive	24 May 2024
				Vebreltinib 200 mg (pts with any baseline brain metastases)	emyqicjmmi(yofztithgu) = mzfyifwreq pxkteiyzlb (zggnwnlfzj )
NCT06105619 (FUGEN, ASCO2024)	Phase 2/3	Glioblastoma PTPRZ1-MET Fusion gene positive	84	Vebreltinib 300 mg	flpkyyzozi(zdyvnqgxat) = ullvtiynsb spgkgvlwgy (xbawgugoes, 4.44 - 8.77) View more	Positive	24 May 2024
				Chemotherapy (temozolomide or cis-platinum combined with etoposide)	flpkyyzozi(zdyvnqgxat) = gamecjwkpu spgkgvlwgy (xbawgugoes, 2.37 - 4.27) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vebreltinib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation